Danielle Sullivan

2.7k citations
27 papers · 1.2k · 1 hit paper · h-index 11

Impact in

    • Breast Cancer Treatment Studies
  • Oncology top 5%
    • PARP inhibition in cancer therapy
    • HER2/EGFR in Cancer Research

Papers in

Danielle Sullivan

27 papers receiving 1.2k citations

Danielle Sullivan's Hit Papers

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial 2018 · 545 citations
5450+2+5Years since publication100200300400500

Peers

Danielle Sullivan
Comparison fields: 5 of 76
  • Cancer Research 345
  • Oncology 597
  • Cellular and Molecular Neuroscience 195
  • Cognitive Neuroscience 204
  • Pulmonary and Respiratory Medicine 142
Replace Wey L. Leong with:
Wey L. Leong Canada
Marco Gymnopoulos United States
Markéta Hermanová Czechia
Michela Croce Italy
Vanessa Vogel Germany
T. Yeatman United States
Lesang Shen China
Minden Collamore United States
Dantong Sun China
Anna Ruiz Spain
Danielle Sullivan relative to Wey L. Leong Canada Wey L. Leong's profile →
Citations per field
00.5×6.4×
Wey L. Leong · 1×
Citations per year

Countries citing papers authored by Danielle Sullivan

Since Specialization
Citations

This map shows the geographic impact of Danielle Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Sullivan more than expected).

Fields of papers citing papers by Danielle Sullivan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Sullivan. The network helps show where Danielle Sullivan may publish in the future.

Co-authors

The 25 scholars most cited alongside Danielle Sullivan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Danielle Sullivan Line = papers co-authored together Danielle Sullivan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Hit paper breakdown →
2018545
2 2011228
3 202094
4 201862
5 201656
6 201749
7 201848
8 201824
9 201323
10 201816
11 202110
12 20219
13 20198
14 20177
15 20157
16 20217
17 20164
18
Abstract 12621: Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance
20132
19 20202
20 20172

About Danielle Sullivan

Danielle Sullivan is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Genetics and Reproductive Medicine, having authored 27 papers that have together received 1.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (10 papers), Cancer Treatment and Pharmacology (4 papers), Lung Cancer Treatments and Mutations (4 papers), Ovarian cancer diagnosis and treatment (3 papers), Hepatitis C virus research (3 papers), DNA Repair Mechanisms (2 papers), BRCA gene mutations in cancer (2 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Cancer Research (345 citations), Oncology (597 citations), Cellular and Molecular Neuroscience (195 citations), Cognitive Neuroscience (204 citations) and Pulmonary and Respiratory Medicine (142 citations). Danielle Sullivan has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include David Maag, Mark D. McKee, Mehra Golshan, Sibylle Loibl, Charles E. Geyer, Otto Metzger, Kamran Diba, Norman Wolmark, Hope S. Rugo and Jens Huober. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Journal of Thoracic Oncology, Journal of Hepatology and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact